WS Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
WS Management's XBI Position: Q1 2026 in Review
WS Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q1 2026, buying an estimated $2.5M and bringing the position to 150,000 shares worth $19.2M. The position accounts for 1.69% of the portfolio, ranked #20.
WS Management first reported a position in XBI in Q2 2022 and has held it in 16 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- WS Management held 150,000 shares of State Street SPDR S&P Biotech ETF worth $19.2M as of Q1 2026.
- WS Management bought 20,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $2.5M.
- State Street SPDR S&P Biotech ETF made up 1.69% of WS Management's portfolio in Q1 2026, its #20 holding.
- WS Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 16 quarters since.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on WS Management's 13F filing for Q1 2026, filed 15 May 2026.